Paper Details 
Original Abstract of the Article :
Commercially available cilostazol (CIL) tablet releases drug immediately and is given twice a day as an antiplatelet and vasodilatory agent. However, clinical usefulness of immediate release (IR) preparation is limited due to its extremely poor water solubility and the difficulty in sustaining the b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.ijpharm.2019.01.004

データ提供:米国国立医学図書館(NLM)

Cilostazol: A Controlled Release Approach for Improved Efficacy

The development of [controlled release medications] is a crucial aspect of [pharmaceutics], aiming to optimize drug delivery and improve therapeutic outcomes. This study explores the potential of a [double controlled release (DCRT)] formulation for [cilostazol], a medication used to treat [peripheral artery disease]. The researchers aimed to enhance the solubility and sustain the blood concentration of cilostazol, potentially improving its efficacy and reducing unwanted side effects.

DCRT Formulation: A Promising Approach for Cilostazol Delivery

This study demonstrates the effectiveness of a [double controlled release (DCRT)] formulation for [cilostazol]. The findings suggest that the DCRT formulation significantly enhanced the solubility and sustained the blood concentration of cilostazol in a controlled manner. This approach could potentially improve the efficacy of cilostazol and minimize unwanted side effects, leading to better therapeutic outcomes for patients.

Optimizing Drug Delivery: A Key to Enhanced Therapeutic Outcomes

This study underscores the importance of optimizing drug delivery for improved therapeutic outcomes. The findings highlight the potential of [double controlled release (DCRT)] formulations in achieving sustained drug release and enhancing drug efficacy. This research could pave the way for more effective and user-friendly medication delivery systems, potentially improving the well-being of patients taking medications like cilostazol.

Dr. Camel's Conclusion

The quest for optimized drug delivery is a journey through a vast desert, filled with challenges and possibilities. This study highlights the potential of a [double controlled release (DCRT)] formulation for [cilostazol] as a promising oasis, offering a path toward improved efficacy and reduced side effects. The findings encourage us to continue exploring and developing innovative drug delivery systems, potentially revolutionizing the way we deliver medications and improve patient outcomes.

Date :
  1. Date Completed 2019-06-13
  2. Date Revised 2019-06-13
Further Info :

Pubmed ID

30641181

DOI: Digital Object Identifier

10.1016/j.ijpharm.2019.01.004

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.